FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4235629817> ?p ?o ?g. }

• W4235629817 endingPage "A288" @default.
• W4235629817 startingPage "A288.3" @default.
• W4235629817 abstract "<h3>Background</h3> Etanercept levels are associated with clinical response in rheumatoid arthritis, however, in a small group of 53 patients with ankylosing spondylitis (AS) this association was not found (de Vries MK et al. ARD 2009). <h3>Objectives</h3> To investigate the relationship between etanercept levels and clinical response in a large cohort of AS patients. <h3>Methods</h3> Prospective observational cohort study of 170 consecutive AS patients treated with etanercept, monitored during 24 weeks of follow-up. Etanercept trough levels were determined retrospectively using an enzyme linked immunosorbent assay (ELISA) designed by Sanquin Research, Amsterdam. Response to etanercept treatment was defined as a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) response (50% improvement or an absolute improvement of 2 points on a BASDAI, scale 0-10) and disease activity was measured using AS Disease Activity Score, including CRP (ASDAS). <h3>Results</h3> Of 170 patients, 122 (71.8%) were male and 130 (82.8%) were HLA-B27 positive. At baseline median BASDAI was 6.0 (IQR 4.8-7.1) and mean ASDAS was 3.5 (SD 1.0). After 24 weeks 98 (57.6%) patients were BASDAI responder (last observation carried forward), mean ASDAS (SD) for responders was 1.6 (0.9) vs. 2.4 (0.9) for non-responders (p<0.001). Of 170 patients 19 dropped out: 16 (84.2%) due to treatment failure or adverse events and 3 (15.8%) due to other reasons. At 24 weeks of treatment etanercept levels were significantly higher in patients with inactive to moderate disease activity (ASDAS <2.1, median (IQR) 3.7 (2.5-5.5)) compared to patients with high to very high disease activity (ASDAS ≥2.1, (median (IQR) 2.3 (1.2-3.7)) (p=0.01). For BASDAI response no significant association with etanercept levels was found. When patients were categorized into quartiles according to the height of etanercept levels at 24 weeks, the lowest quartile (etanercept level < 1.8 mg/L) comprised 35.1% of all patients with ASDAS ≥2.1. The highest quartile (etanercept level > 5.0 mg/L) comprised 33.8% of all patients with ASDAS <2.1. <h3>Image/graph</h3> <h3>Conclusions</h3> Lower etanercept levels in AS are associated with high disease activity at 24 weeks of treatment. <h3>Disclosure of Interest</h3> E. Kneepkens: None Declared, C. Krieckaert: None Declared, M. Nurmohamed Grant/research support from: Abbott, Roche, Pfizer, Consultant for: Abbott, Roche, Pfizer, MSD, UCB, SOBI and BMS, Speakers bureau: Abbott, Roche, Pfizer, I. van der Horst-Bruinsma: None Declared, G. Wolbink Grant/research support from: Pfizer, Speakers bureau: Pfizer, Amgen" @default.
• W4235629817 created "2022-05-12" @default.
• W4235629817 creator A5017243329 @default.
• W4235629817 creator A5020028106 @default.
• W4235629817 creator A5029733252 @default.
• W4235629817 creator A5042768514 @default.
• W4235629817 creator A5053902058 @default.
• W4235629817 date "2013-06-01" @default.
• W4235629817 modified "2023-09-25" @default.
• W4235629817 title "THU0364 Lower Etanercept Levels are Associated with High Disease Activity in Ankylosing Spondylitis Patients at 24 Weeks of Follow-Up" @default.
• W4235629817 doi "https://doi.org/10.1136/annrheumdis-2013-eular.892" @default.
• W4235629817 hasPublicationYear "2013" @default.
• W4235629817 type Work @default.
• W4235629817 citedByCount "0" @default.
• W4235629817 crossrefType "journal-article" @default.
• W4235629817 hasAuthorship W4235629817A5017243329 @default.
• W4235629817 hasAuthorship W4235629817A5020028106 @default.
• W4235629817 hasAuthorship W4235629817A5029733252 @default.
• W4235629817 hasAuthorship W4235629817A5042768514 @default.
• W4235629817 hasAuthorship W4235629817A5053902058 @default.
• W4235629817 hasConcept C126322002 @default.
• W4235629817 hasConcept C188816634 @default.
• W4235629817 hasConcept C197934379 @default.
• W4235629817 hasConcept C201903717 @default.
• W4235629817 hasConcept C2776260265 @default.
• W4235629817 hasConcept C2777226972 @default.
• W4235629817 hasConcept C2777402515 @default.
• W4235629817 hasConcept C2777453003 @default.
• W4235629817 hasConcept C2777575956 @default.
• W4235629817 hasConcept C2779650986 @default.
• W4235629817 hasConcept C2779722408 @default.
• W4235629817 hasConcept C71924100 @default.
• W4235629817 hasConcept C72563966 @default.
• W4235629817 hasConcept C90924648 @default.
• W4235629817 hasConceptScore W4235629817C126322002 @default.
• W4235629817 hasConceptScore W4235629817C188816634 @default.
• W4235629817 hasConceptScore W4235629817C197934379 @default.
• W4235629817 hasConceptScore W4235629817C201903717 @default.
• W4235629817 hasConceptScore W4235629817C2776260265 @default.
• W4235629817 hasConceptScore W4235629817C2777226972 @default.
• W4235629817 hasConceptScore W4235629817C2777402515 @default.
• W4235629817 hasConceptScore W4235629817C2777453003 @default.
• W4235629817 hasConceptScore W4235629817C2777575956 @default.
• W4235629817 hasConceptScore W4235629817C2779650986 @default.
• W4235629817 hasConceptScore W4235629817C2779722408 @default.
• W4235629817 hasConceptScore W4235629817C71924100 @default.
• W4235629817 hasConceptScore W4235629817C72563966 @default.
• W4235629817 hasConceptScore W4235629817C90924648 @default.
• W4235629817 hasIssue "Suppl 3" @default.
• W4235629817 hasLocation W42356298171 @default.
• W4235629817 hasOpenAccess W4235629817 @default.
• W4235629817 hasPrimaryLocation W42356298171 @default.
• W4235629817 hasRelatedWork W2052177228 @default.
• W4235629817 hasRelatedWork W2096703320 @default.
• W4235629817 hasRelatedWork W2111965497 @default.
• W4235629817 hasRelatedWork W2171255147 @default.
• W4235629817 hasRelatedWork W2324806691 @default.
• W4235629817 hasRelatedWork W2411482347 @default.
• W4235629817 hasRelatedWork W2412912224 @default.
• W4235629817 hasRelatedWork W2913836612 @default.
• W4235629817 hasRelatedWork W3032960390 @default.
• W4235629817 hasRelatedWork W4235629817 @default.
• W4235629817 hasVolume "72" @default.
• W4235629817 isParatext "false" @default.
• W4235629817 isRetracted "false" @default.
• W4235629817 workType "article" @default.